WO1996038418A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5908858A
(en)
*
|
1996-04-05 |
1999-06-01 |
Sankyo Company, Limited |
1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
|
ATE408607T1
(de)
*
|
1996-04-12 |
2008-10-15 |
Searle Llc |
Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
|
US6586458B1
(en)
|
1996-08-16 |
2003-07-01 |
Pozen Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US8022095B2
(en)
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
EP0971714B1
(en)
*
|
1997-04-03 |
2002-10-09 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
|
US20040072889A1
(en)
*
|
1997-04-21 |
2004-04-15 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
|
RS49982B
(sr)
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
NZ333399A
(en)
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
US6136804A
(en)
*
|
1998-03-13 |
2000-10-24 |
Merck & Co., Inc. |
Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
|
WO1999045913A1
(en)
*
|
1998-03-13 |
1999-09-16 |
Merck & Co., Inc. |
Combination therapy and composition for acute coronary ischemic syndrome and related conditions
|
AU4428899A
(en)
|
1998-06-08 |
1999-12-30 |
Advanced Medicine, Inc. |
Multibinding inhibitors of cyclooxygenase-2
|
AR024222A1
(es)
*
|
1998-10-16 |
2002-09-25 |
Palau Pharma Sa |
Imidazoles con actividad antiinflamatoria un procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
|
CA2348979A1
(en)
*
|
1998-11-02 |
2000-05-11 |
Merck & Co., Inc. |
Method of treating migraines and pharmaceutical compositions
|
WO2000029022A1
(en)
*
|
1998-11-12 |
2000-05-25 |
Algos Pharmaceutical Corporation |
Cox-2 inhibitors in combination with centrally acting analgesics
|
US6649645B1
(en)
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
US20040122011A1
(en)
*
|
1998-12-23 |
2004-06-24 |
Pharmacia Corporation |
Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
|
WO2000048583A2
(en)
*
|
1999-02-19 |
2000-08-24 |
Pozen Inc. |
Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
|
US20010024664A1
(en)
*
|
1999-03-19 |
2001-09-27 |
Obukowicz Mark G. |
Selective COX-2 inhibition from edible plant extracts
|
US6323226B1
(en)
|
1999-10-19 |
2001-11-27 |
Texas Heart Institute |
Treatment of heart disease with cox-2 inhibitors
|
SK12672001A3
(sk)
*
|
1999-12-08 |
2002-04-04 |
Pharmacia Corporation |
Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
|
NZ519467A
(en)
*
|
1999-12-22 |
2004-02-27 |
Pharmacia Corp |
Dual-release compositions of a cyclooxygenase-2- inhibitor
|
MXPA02006312A
(es)
|
1999-12-23 |
2004-06-21 |
Nitromed Inc |
Inhibidores de ciclooxigenasa-2 nitrosilatados y nitrosados, composiciones y metodos para utilizarse.
|
IL151299A0
(en)
|
2000-02-16 |
2003-04-10 |
Brigham & Womens Hospital |
Aspirin-triggered lipid mediators
|
AU3217501A
(en)
|
2000-03-03 |
2001-09-12 |
Pfizer Prod Inc |
Pyrazole ether derivatives as anti-inflammatory/analgesic agents
|
US20070072861A1
(en)
*
|
2000-03-27 |
2007-03-29 |
Barbara Roniker |
Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
|
ES2166710B1
(es)
*
|
2000-04-25 |
2004-10-16 |
J. URIACH & CIA, S.A. |
Nuevos compuestos heterociclicos con actividad antiinflamatoria.
|
AU2001253749A1
(en)
*
|
2000-04-25 |
2001-11-07 |
Pharmacia Corporation |
2-fluorobenzenesulfonyl compounds for the treatment of inflammation
|
AU5754701A
(en)
*
|
2000-07-13 |
2002-01-30 |
Pharmacia Corp |
Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
|
HUP0302068A3
(en)
|
2000-07-20 |
2005-05-30 |
Lauras As |
Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
|
US20030219461A1
(en)
*
|
2000-09-12 |
2003-11-27 |
Britten Nancy J. |
Parenteral combination therapy for infective conditions
|
AU2001295038A1
(en)
*
|
2000-09-18 |
2002-03-26 |
Merck & Co., Inc. |
Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-V antagonist
|
EP1578341A2
(en)
*
|
2000-10-11 |
2005-09-28 |
Tularik Inc. |
Modulation of ccr4 function
|
EP1401460A2
(en)
*
|
2000-12-15 |
2004-03-31 |
Pharmacia Corporation |
Selective cox-2 inhibition from plant extracts
|
WO2002047707A2
(en)
*
|
2000-12-15 |
2002-06-20 |
Pharmacia Corporation |
Selective cox-2 inhibition from non-edible plant extracts
|
EP1406609B1
(en)
|
2000-12-21 |
2006-09-06 |
Nitromed, Inc. |
Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
WO2002062391A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Pharmacia Corporation |
Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
|
WO2002078625A2
(en)
*
|
2001-03-28 |
2002-10-10 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
PE20021017A1
(es)
*
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US20030105144A1
(en)
*
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
*
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
US7144903B2
(en)
*
|
2001-05-23 |
2006-12-05 |
Amgen Inc. |
CCR4 antagonists
|
US20030153801A1
(en)
*
|
2001-05-29 |
2003-08-14 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
|
HUP0600294A2
(en)
*
|
2001-05-31 |
2007-02-28 |
Pharmacia Corp |
Skin-permeable selective cyclooxygenase-2 inhibitor composition
|
US20060167074A1
(en)
*
|
2001-06-19 |
2006-07-27 |
Norbert Muller |
Methods and compositions for the treatment of psychiatric disorders
|
DE10129320A1
(de)
*
|
2001-06-19 |
2003-04-10 |
Norbert Mueller |
Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
US20040067992A1
(en)
*
|
2001-08-10 |
2004-04-08 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
|
CA2456939A1
(en)
*
|
2001-08-10 |
2003-02-20 |
Pharmacia Corporation |
Carbonic anhydrase inhibitors
|
US20050101563A1
(en)
*
|
2001-08-14 |
2005-05-12 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation
|
US20030114416A1
(en)
*
|
2001-08-14 |
2003-06-19 |
Pharmacia Corporation |
Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
BR0212435A
(pt)
*
|
2001-09-10 |
2004-08-17 |
Sugen Inc |
Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
|
WO2003024400A2
(en)
|
2001-09-18 |
2003-03-27 |
Onconova Therapeutics, Inc. |
Process for the preparation of 1,5-diarylpyrazoles
|
US20030114483A1
(en)
*
|
2001-09-18 |
2003-06-19 |
Pharmacia Corporation |
Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
US20030236308A1
(en)
*
|
2001-09-18 |
2003-12-25 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
|
EP1436285A4
(en)
*
|
2001-09-18 |
2004-12-15 |
Onconova Therapeutics Inc |
METHOD FOR PRODUCING 1,5-DIARYL-3-SUBSTITUTED PYRAZOLES
|
ES2286275T3
(es)
|
2001-09-19 |
2007-12-01 |
Pharmacia Corporation |
Compuestos de pirazolo sustituidos para el tratamiento de la inflamacion.
|
RU2284324C2
(ru)
*
|
2001-10-02 |
2006-09-27 |
Фармация Корпорейшн |
Способ получения бензолсульфонилов
|
AR037097A1
(es)
|
2001-10-05 |
2004-10-20 |
Novartis Ag |
Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
|
WO2003031404A2
(en)
*
|
2001-10-12 |
2003-04-17 |
Onconova Therapeutics, Inc. |
Processes for the preparation of substituted isoxazoles and 2-isoxazolines
|
US20030162824A1
(en)
*
|
2001-11-12 |
2003-08-28 |
Krul Elaine S. |
Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
|
AR037356A1
(es)
*
|
2001-11-13 |
2004-11-03 |
Pharmacia Corp |
Forma de dosificacion oral de una prodroga de sulfonamida
|
EP1551812B1
(en)
|
2001-12-06 |
2009-03-04 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
CA2470214A1
(en)
*
|
2001-12-13 |
2003-06-26 |
Abbott Laboratories |
3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
|
US20040126438A1
(en)
*
|
2001-12-13 |
2004-07-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from plant extracts
|
US20040062823A1
(en)
*
|
2001-12-13 |
2004-04-01 |
Obukowicz Mark G. |
Selective cox-2 inhibition from non-edible plant extracts
|
KR20040072720A
(ko)
*
|
2002-01-10 |
2004-08-18 |
파마시아 앤드 업존 캄파니 |
항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 cox-2 억제제의 용도
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
US20030212138A1
(en)
*
|
2002-01-14 |
2003-11-13 |
Pharmacia Corporation |
Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
|
TW200403072A
(en)
*
|
2002-01-23 |
2004-03-01 |
Upjohn Co |
Combination therapy for the treatment of bacterial infections
|
US20100311701A1
(en)
*
|
2002-02-15 |
2010-12-09 |
Transform Pharmaceuticals, Inc |
Pharmaceutical Co-Crystal Compositions
|
US20050025791A1
(en)
*
|
2002-06-21 |
2005-02-03 |
Julius Remenar |
Pharmaceutical compositions with improved dissolution
|
US7927613B2
(en)
*
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
*
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
EP1915992A1
(en)
|
2002-02-19 |
2008-04-30 |
Pharmacia Corporation |
Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
|
AU2003213719A1
(en)
*
|
2002-03-01 |
2003-09-16 |
Regents Of The University Of Michigan |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
KR100763045B1
(ko)
*
|
2002-03-15 |
2007-10-04 |
파마시아 코포레이션 |
파레콕시브 나트륨 결정체
|
US8481772B2
(en)
|
2002-04-01 |
2013-07-09 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid derivatives
|
US7902257B2
(en)
|
2002-04-01 |
2011-03-08 |
University Of Southern California |
Trihydroxy polyunsaturated eicosanoid
|
AU2003216920A1
(en)
|
2002-04-08 |
2003-10-20 |
Glaxo Group Limited |
(2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
|
EP1494664A2
(en)
*
|
2002-04-18 |
2005-01-12 |
Pharmacia Corporation |
Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
|
EP1505962A2
(en)
*
|
2002-04-18 |
2005-02-16 |
Pharmacia Corporation |
Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)
|
US7273616B2
(en)
*
|
2002-05-10 |
2007-09-25 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
|
WO2004002533A1
(en)
*
|
2002-06-26 |
2004-01-08 |
Pharmacia Corporation |
Stable liquid parenteral parecoxib formulation
|
EP1534683A4
(en)
|
2002-06-27 |
2005-08-24 |
Nitromed Inc |
CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
|
JP2005535642A
(ja)
|
2002-06-28 |
2005-11-24 |
ニトロメッド インコーポレーティッド |
オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
|
WO2004004833A1
(en)
*
|
2002-07-02 |
2004-01-15 |
Pharmacia Corporation |
Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
|
CA2495260C
(en)
*
|
2002-08-12 |
2012-05-29 |
Brigham And Women's Hospital |
Resolvins: biotemplates for novel therapeutic interventions
|
US7759395B2
(en)
*
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
AU2003267231A1
(en)
*
|
2002-09-20 |
2004-04-08 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical compositions with improved dissolution
|
KR100484525B1
(ko)
*
|
2002-10-15 |
2005-04-20 |
씨제이 주식회사 |
이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
|
US20040082543A1
(en)
*
|
2002-10-29 |
2004-04-29 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
|
GB0225548D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Compounds
|
US20040092566A1
(en)
*
|
2002-11-12 |
2004-05-13 |
Graneto Matthew J. |
Celecoxib prodrug
|
US20040147581A1
(en)
*
|
2002-11-18 |
2004-07-29 |
Pharmacia Corporation |
Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
|
US20040127531A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
|
US20050020658A1
(en)
*
|
2002-11-21 |
2005-01-27 |
Katsuyuki Inoo |
Selective cyclooxygenase-2 inhibitor patch
|
US20040126415A1
(en)
*
|
2002-11-21 |
2004-07-01 |
Lu Guang Wei |
Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
|
NZ567457A
(en)
|
2002-12-13 |
2009-08-28 |
Warner Lambert Co |
Alpha-2-delta ligand to treat lower urinary tract symptoms
|
US20040235925A1
(en)
*
|
2002-12-17 |
2004-11-25 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20040204411A1
(en)
*
|
2002-12-17 |
2004-10-14 |
Pharmacia Corporation |
Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
|
US20040157848A1
(en)
*
|
2002-12-19 |
2004-08-12 |
Pharmacia Corporation |
Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
|
US20080153894A1
(en)
*
|
2002-12-19 |
2008-06-26 |
Pharmacia Corporation |
Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
|
AU2003300264A1
(en)
*
|
2002-12-20 |
2004-07-22 |
Pharmacia Corporation |
Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
|
ES2215474B1
(es)
|
2002-12-24 |
2005-12-16 |
J. URIACH & CIA S.A. |
Nuevos derivados de fosforamida.
|
JP4616009B2
(ja)
|
2002-12-26 |
2011-01-19 |
ポーゼン インコーポレイテッド |
NSAIDsおよびトリプタンを含有する多層剤型
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
WO2004060367A1
(en)
*
|
2002-12-30 |
2004-07-22 |
Fujisawa Pharmaceutical Co., Ltd. |
Imidazole and triazole derivatives useful as selective cox-1 inhibitors
|
US20050026902A1
(en)
*
|
2003-01-31 |
2005-02-03 |
Timothy Maziasz |
Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
|
US20040176378A1
(en)
*
|
2003-02-12 |
2004-09-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
|
WO2004078143A2
(en)
*
|
2003-03-05 |
2004-09-16 |
The Brigham And Women's Hospital Inc. |
Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
|
US20050004098A1
(en)
*
|
2003-03-20 |
2005-01-06 |
Britten Nancy Jean |
Dispersible formulation of an anti-inflammatory agent
|
US20050009931A1
(en)
*
|
2003-03-20 |
2005-01-13 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
WO2004082588A2
(en)
*
|
2003-03-20 |
2004-09-30 |
Pharmacia Corporation |
Dispersible formulation of an anti-inflammatory agent
|
US20040214753A1
(en)
*
|
2003-03-20 |
2004-10-28 |
Britten Nancy Jean |
Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
|
US20040220155A1
(en)
*
|
2003-03-28 |
2004-11-04 |
Pharmacia Corporation |
Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
|
US20040214861A1
(en)
*
|
2003-03-28 |
2004-10-28 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
|
US20050143431A1
(en)
*
|
2003-04-04 |
2005-06-30 |
Hetero Drugs Limited |
Novel crystalline forms of parecoxib sodium
|
JP2006524248A
(ja)
*
|
2003-04-14 |
2006-10-26 |
ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー |
糖尿病の治療用のn−(((((1,3−チアゾール−2−イル)アミノ)カルボニル)フェニル)スルホニル)フェニルアラニン誘導体及び関連化合物
|
US20040224940A1
(en)
*
|
2003-04-22 |
2004-11-11 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of central nervous system damage
|
WO2004093895A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
|
US20040220187A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
|
US20050009733A1
(en)
*
|
2003-04-22 |
2005-01-13 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
|
US20060135506A1
(en)
*
|
2003-04-22 |
2006-06-22 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
|
WO2004093816A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Pharmacia Corporation |
Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
|
KR20060006953A
(ko)
|
2003-04-30 |
2006-01-20 |
디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 |
치환된 카르복실산
|
US20040220167A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Nasrollah Samiy |
Methods of treating neuralgic pain
|
PL1534305T3
(pl)
|
2003-05-07 |
2007-03-30 |
Osteologix As |
Leczenie zaburzeń chrząstek i kości solami strontu rozpuszczalnymi w wodzie
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004103283A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
|
WO2004103286A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
|
MXPA05012273A
(es)
*
|
2003-05-14 |
2006-02-10 |
Pharmacia Corp |
Composiciones para el tratamiento de la reduccion del flujo sanguineo.
|
WO2004103284A2
(en)
*
|
2003-05-14 |
2004-12-02 |
Pharmacia Corporation |
Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
|
US20050113376A1
(en)
*
|
2003-05-27 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury
|
WO2004105699A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
|
US7923467B2
(en)
|
2003-05-30 |
2011-04-12 |
Ranbaxy Laboratories, Inc. |
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
WO2005016243A2
(en)
*
|
2003-06-09 |
2005-02-24 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders
|
JP2007522084A
(ja)
*
|
2003-06-24 |
2007-08-09 |
ファルマシア・コーポレーション |
悪心を伴う片頭痛の治療
|
US20050101597A1
(en)
*
|
2003-07-10 |
2005-05-12 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
|
WO2005007156A1
(en)
*
|
2003-07-10 |
2005-01-27 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin ii receptor antagonist for the treatment of central nervous system damage
|
WO2005016249A2
(en)
*
|
2003-07-11 |
2005-02-24 |
Pharmacia Corporation |
Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ace inhibitor for the treatment of central nervous system damage
|
US20050080084A1
(en)
*
|
2003-07-11 |
2005-04-14 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin-modulating agent for the treatment of central nervous system damage
|
WO2005009342A2
(en)
*
|
2003-07-16 |
2005-02-03 |
Pharmacia Corporation |
Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
|
WO2005009354A2
(en)
*
|
2003-07-17 |
2005-02-03 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
|
WO2005012268A1
(ja)
*
|
2003-07-30 |
2005-02-10 |
Shionogi & Co., Ltd. |
イソオキサゾール環を有するスルホンアミド誘導体
|
CA2536173A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
US20050119262A1
(en)
*
|
2003-08-21 |
2005-06-02 |
Pharmacia Corporation |
Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
|
US20050085478A1
(en)
*
|
2003-08-22 |
2005-04-21 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
|
US20050107350A1
(en)
*
|
2003-08-22 |
2005-05-19 |
Pharmacia Corporation |
Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
|
JP2007503396A
(ja)
*
|
2003-08-22 |
2007-02-22 |
ファルマシア コーポレイション |
新形成の治療のためのシクロオキシゲナーゼ−2選択的阻害剤及びセロトニン−調節剤の組成物
|
US20050130971A1
(en)
*
|
2003-08-22 |
2005-06-16 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
|
US20050085479A1
(en)
*
|
2003-08-27 |
2005-04-21 |
Pharmacia Corporation |
Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
|
US7282519B2
(en)
*
|
2003-08-28 |
2007-10-16 |
Nitromed, Inc. |
Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
WO2005023189A2
(en)
*
|
2003-09-03 |
2005-03-17 |
Pharmacia Corporation |
Method of cox-2 selective inhibitor and nitric oxide-donating agent
|
US20050113434A1
(en)
*
|
2003-10-03 |
2005-05-26 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
|
CA2545731A1
(en)
*
|
2003-11-12 |
2005-05-26 |
Pharmacia & Upjohn Company |
Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
|
WO2005065684A1
(en)
*
|
2003-12-24 |
2005-07-21 |
Pharmacia Corporation |
Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
|
JP2007518788A
(ja)
|
2004-01-22 |
2007-07-12 |
ファイザー・インク |
バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
|
US20050238589A1
(en)
*
|
2004-04-14 |
2005-10-27 |
Van Dyke Thomas E |
Methods and compositions for preventing or treating periodontal diseases
|
JP2007534740A
(ja)
*
|
2004-04-28 |
2007-11-29 |
ファイザー・インク |
バソプレッシンV1a受容体の阻害剤としての3−ヘテロシクリル−4−フェニル−トリアゾール誘導体
|
BRPI0512832A
(pt)
|
2004-07-01 |
2008-04-08 |
Merck & Co Inc |
composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto
|
ES2257929B1
(es)
|
2004-07-16 |
2007-05-01 |
Laboratorios Del Dr. Esteve, S.A. |
Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
|
CN101014369A
(zh)
*
|
2004-07-22 |
2007-08-08 |
法玛西亚公司 |
利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
CA2576279A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
AR052429A1
(es)
|
2004-12-23 |
2007-03-21 |
Glaxo Group Ltd |
Compuesto de arilpiridina, composicion farmaceutica que lo comprende, su uso para l a eleboracion de un medicamento y procedimiento para prepararlo
|
AU2006206249A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nicox S.A. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
JP2008530226A
(ja)
*
|
2005-02-16 |
2008-08-07 |
ニトロメッド インコーポレーティッド |
抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
|
US7521435B2
(en)
|
2005-02-18 |
2009-04-21 |
Pharma Diagnostics, N.V. |
Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
|
AU2006218766A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nicox S.A. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
KR100990027B1
(ko)
|
2005-04-26 |
2010-10-26 |
화이자 인코포레이티드 |
P-카드헤린 항체
|
WO2006121887A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Cook Biotech Incorporated |
Implantable materials and methods for inhibiting tissue adhesion formation
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
CA2608718A1
(en)
*
|
2005-05-18 |
2006-11-23 |
Pfizer Limited |
1, 2, 4-triazole derivatives as vasopressin antagonists
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
HUP0500730A2
(en)
*
|
2005-07-29 |
2007-02-28 |
Richter Gedeon Vegyuszeti Gyar |
1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
|
EP1915157A4
(en)
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
NICKEL OXYGENIZING ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND USE PROCESSES
|
TWI387592B
(zh)
*
|
2005-08-30 |
2013-03-01 |
Novartis Ag |
經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
|
RS54393B1
(sr)
*
|
2005-09-07 |
2016-04-28 |
Amgen Fremont Inc. |
Humana monoklonska antitela na kinazu-1 sličnu aktivinskom receptoru
|
US8273792B2
(en)
*
|
2005-10-03 |
2012-09-25 |
The Brigham And Women's Hospital, Inc. |
Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
|
US20090054381A1
(en)
*
|
2005-10-04 |
2009-02-26 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
WO2007054896A1
(en)
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
EP1954685A4
(en)
*
|
2005-11-16 |
2009-11-11 |
Nitromed Inc |
FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
|
WO2007061783A1
(en)
|
2005-11-18 |
2007-05-31 |
Trustees Of Boston University |
Treatment and prevention of bone loss using resolvins
|
EP1968584A2
(en)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
NL2000351C2
(nl)
|
2005-12-22 |
2007-09-11 |
Pfizer Prod Inc |
Estrogeen-modulatoren.
|
US20090062302A1
(en)
|
2006-01-24 |
2009-03-05 |
Buser-Doepner Carolyn A |
Jak2 Tyrosine Kinase Inhibition
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2007126609A1
(en)
|
2006-03-29 |
2007-11-08 |
Nitromed, Inc. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
WO2007121484A2
(en)
|
2006-04-19 |
2007-10-25 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
EP2027087A2
(en)
|
2006-05-18 |
2009-02-25 |
MannKind Corporation |
Intracellular kinase inhibitors
|
WO2008033931A1
(en)
*
|
2006-09-13 |
2008-03-20 |
The Institutes For Pharmaceutical Discovery, Llc |
Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
RS51940B
(sr)
|
2006-12-22 |
2012-02-29 |
Recordati Ireland Limited |
KOMBINOVANA TERAPIJA LIGANADA α2δ I NSAID ZA POREMEĆAJE DONjEG URINARNOG TRAKTA
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
KR100843351B1
(ko)
*
|
2007-01-30 |
2008-07-03 |
한국과학기술연구원 |
중추신경계 질환 치료제로 유효한n-벤질-n-(2-디메틸아미노-에틸)-벤젠술폰아미드 화합물
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
GB0704407D0
(en)
|
2007-03-07 |
2007-04-18 |
Glaxo Group Ltd |
Compounds
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US8247423B2
(en)
|
2007-07-12 |
2012-08-21 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
EP2200607A4
(en)
|
2007-09-10 |
2012-02-22 |
Calcimedica Inc |
COMPOUNDS MODULATING INTRACELLULAR CALCIUM
|
JP2011515343A
(ja)
|
2008-03-03 |
2011-05-19 |
タイガー ファーマテック |
チロシンキナーゼ阻害薬
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
BRPI0917719A2
(pt)
|
2008-08-27 |
2019-11-19 |
Calcimedica Inc |
compostos que modulam cálcio intracelular
|
EP2177215A1
(en)
|
2008-10-17 |
2010-04-21 |
Laboratorios Del. Dr. Esteve, S.A. |
Co-crystals of tramadol and NSAIDs
|
JP5212177B2
(ja)
*
|
2009-02-27 |
2013-06-19 |
東レ株式会社 |
γ−ケトアセタール化合物及びピロール誘導体の製造方法
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
KR101069175B1
(ko)
|
2009-04-19 |
2011-09-30 |
중앙대학교 산학협력단 |
신규 아미노설포닐아릴이소옥사졸계 화합물 및 이를 포함하는 다약제내성 억제용 약제학적 조성물
|
WO2011012622A1
(en)
|
2009-07-30 |
2011-02-03 |
Glaxo Group Limited |
Benzoxazinone derivatives for the treatment of glytl mediated disorders
|
WO2011023753A1
(en)
|
2009-08-27 |
2011-03-03 |
Glaxo Group Limited |
Benzoxazine derivatives as glycine transport inhibitors
|
CN102638981B
(zh)
|
2009-10-14 |
2015-07-22 |
默沙东公司 |
提高p53活性的取代的哌啶和其用途
|
GB201000685D0
(en)
|
2010-01-15 |
2010-03-03 |
Glaxo Group Ltd |
Novel compounds
|
CN101805290A
(zh)
*
|
2010-04-01 |
2010-08-18 |
中国人民解放军第四军医大学 |
氨基磺酰吡唑类化合物及其用途
|
PT2563776T
(pt)
|
2010-04-27 |
2016-09-19 |
Calcimedica Inc |
Compostos que modulam o cálcio intracelular
|
US8754219B2
(en)
|
2010-04-27 |
2014-06-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
EP2571860A1
(en)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl benzoylamides
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
WO2012004604A1
(en)
|
2010-07-09 |
2012-01-12 |
Convergence Pharmaceuticals Limited |
Tetrazole compounds as calcium channel blockers
|
CA2805265A1
(en)
|
2010-08-02 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
PL2606044T3
(pl)
*
|
2010-08-20 |
2014-09-30 |
Allergan Inc |
Związki, które działają na wiele receptorów prostaglandyn, wywołujące ogólną odpowiedź przeciwzapalną
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
MX337711B
(es)
|
2010-08-27 |
2016-03-15 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US8933132B2
(en)
|
2011-01-19 |
2015-01-13 |
Convergence Pharmaceuticals Limited |
Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers
|
US20130345392A1
(en)
|
2011-03-04 |
2013-12-26 |
Pfizer Inc |
Edn3-like peptides and uses thereof
|
JP2014514321A
(ja)
|
2011-04-21 |
2014-06-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
インスリン様増殖因子1受容体阻害剤
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2013066729A1
(en)
|
2011-10-31 |
2013-05-10 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
|
JP2015501802A
(ja)
*
|
2011-11-17 |
2015-01-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate |
眼への薬物送達を向上させるための方法および組成物、ならびに徐放性送達製剤
|
GB201122113D0
(en)
|
2011-12-22 |
2012-02-01 |
Convergence Pharmaceuticals |
Novel compounds
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
BR112015013611A2
(pt)
|
2012-12-20 |
2017-11-14 |
Merck Sharp & Dohme |
composto, e, composição farmacêutica
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
KR102230461B1
(ko)
*
|
2013-03-15 |
2021-03-22 |
유니버시티 오브 써던 캘리포니아 |
엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들
|
EP3019171B1
(en)
|
2013-07-11 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN104418818B
(zh)
*
|
2013-09-04 |
2017-01-11 |
天津汉瑞药业有限公司 |
帕瑞昔布钠无水化合物
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CN105085425B
(zh)
*
|
2014-05-23 |
2018-01-30 |
昆药集团股份有限公司 |
一种制备帕瑞昔布的方法
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
GB201417499D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417500D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
GB201417497D0
(en)
|
2014-10-03 |
2014-11-19 |
Convergence Pharmaceuticals |
Novel use
|
CN104557754A
(zh)
*
|
2015-01-04 |
2015-04-29 |
成都克莱蒙医药科技有限公司 |
一种帕瑞昔布钠杂质的合成方法
|
EP3267996B1
(en)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of irak4 activity
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
EP3268367B8
(en)
|
2015-03-12 |
2022-11-16 |
Merck Sharp & Dohme LLC |
Carboxamide inhibitors of irak4 activity
|
US9598361B1
(en)
*
|
2016-04-12 |
2017-03-21 |
King Saud University |
Amino substituted acetamide derivative
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
CN108299331A
(zh)
*
|
2018-03-02 |
2018-07-20 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠光降解杂质及其制备、检测方法和应用
|
CN108164521B
(zh)
*
|
2018-03-02 |
2020-11-13 |
成都新恒创药业有限公司 |
一种帕瑞昔布钠降解杂质及其制备、检测方法和应用
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
CN110305071A
(zh)
*
|
2019-07-23 |
2019-10-08 |
成都通德药业有限公司 |
一种帕瑞昔布钠中间体帕瑞昔布的合成方法
|
EP4077282A4
(en)
|
2019-12-17 |
2023-11-08 |
Merck Sharp & Dohme LLC |
PRMT5 INHIBITORS
|
CA3209491A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
|